Arbutus biopharma appoints tram tran, m.d. to its board of directors

Warminster, pa., nov. 11, 2021 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a cure for people with chronic hepatitis b virus (hbv) infection and to treat coronaviruses (including covid-19), today announced that tram tran, m.d. has been appointed to the arbutus board of directors effective immediately. dr. tran is a renowned liver and viral specialist with over 20 years of academic and industry experience as a physician scientist.
ABUS Ratings Summary
ABUS Quant Ranking